Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Genetic and phenotypic diversity in breast tumor metastases.

Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K.

Cancer Res. 2014 Mar 1;74(5):1338-48. doi: 10.1158/0008-5472.CAN-13-2357-T. Epub 2014 Jan 21.

2.

Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.

Rivenbark AG, Livasy CA, Boyd CE, Keppler D, Coleman WB.

Exp Mol Pathol. 2007 Oct;83(2):188-97. Epub 2007 Apr 18.

3.

Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.

Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR.

Breast Cancer Res Treat. 2007 Apr;102(2):143-55. Epub 2006 Aug 9.

PMID:
16906480
4.

The genomic heritage of lymph node metastases: implications for clinical management of patients with breast cancer.

Becker TE, Ellsworth RE, Deyarmin B, Patney HL, Jordan RM, Hooke JA, Shriver CD, Ellsworth DL.

Ann Surg Oncol. 2008 Apr;15(4):1056-63. doi: 10.1245/s10434-008-9815-3. Epub 2008 Feb 2.

PMID:
18246400
5.

Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization.

Nishizaki T, DeVries S, Chew K, Goodson WH 3rd, Ljung BM, Thor A, Waldman FM.

Genes Chromosomes Cancer. 1997 Aug;19(4):267-72.

PMID:
9258662
6.

MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.

Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P.

Mod Pathol. 2012 Mar;25(3):378-87. doi: 10.1038/modpathol.2011.171. Epub 2011 Nov 4.

7.

Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M, Rydén L.

Breast Cancer Res Treat. 2013 Jul;140(1):93-104. doi: 10.1007/s10549-013-2617-8. Epub 2013 Jun 27.

PMID:
23807420
8.

Allelotype analysis of flow-sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases.

Bonsing BA, Corver WE, Fleuren GJ, Cleton-Jansen AM, Devilee P, Cornelisse CJ.

Genes Chromosomes Cancer. 2000 Jun;28(2):173-83.

PMID:
10825002
9.

Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?

Falck AK, Fernö M, Bendahl PO, Rydén L.

World J Surg. 2010 Jul;34(7):1434-41. doi: 10.1007/s00268-010-0499-z.

PMID:
20213203
10.

Chromosomal genotype in breast cancer progression: comparison of primary and secondary manifestations.

Friedrich K, Weber T, Scheithauer J, Meyer W, Haroske G, Kunze KD, Baretton G.

Cell Oncol. 2008;30(1):39-50.

11.

The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells.

Workman HC, Miller JK, Ingalla EQ, Kaur RP, Yamamoto DI, Beckett LA, Young LJ, Cardiff RD, Borowsky AD, Carraway KL, Sweeney C, Carraway KL 3rd.

Breast Cancer Res. 2009;11(5):R70. doi: 10.1186/bcr2364.

12.

[Comparison of HER2 gene status between primary breast cancer and synchronous axillary lymph node metastasis].

Liu YY, Wu SF, Liang ZY, Zeng X.

Zhonghua Bing Li Xue Za Zhi. 2016 Jun 8;45(6):393-6. doi: 10.3760/cma.j.issn.0529-5807.2016.06.008. Chinese.

PMID:
27256047
13.

Evidence for limited molecular genetic heterogeneity as defined by allelotyping and clonal analysis in nine metastatic breast carcinomas.

Bonsing BA, Devilee P, Cleton-Jansen AM, Kuipers-Dijkshoorn N, Fleuren GJ, Cornelisse CJ.

Cancer Res. 1993 Aug 15;53(16):3804-11.

15.

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.

Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C.

Br J Cancer. 2004 Jun 14;90(12):2344-8. Review.

16.

HER2 gene status in primary breast cancers and matched distant metastases.

Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G, Terracciano L, Feichter G, Bubendorf L.

Breast Cancer Res. 2007;9(3):R31.

17.

Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.

Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB.

Mod Pathol. 2002 Jan;15(1):35-44.

18.

Clonal origin of lymph node metastases in bladder carcinoma.

Jones TD, Carr MD, Eble JN, Wang M, Lopez-Beltran A, Cheng L.

Cancer. 2005 Nov 1;104(9):1901-10.

19.

Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.

Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, D'Argento E, Cassano A, Schinzari G, Barone C.

Clin Breast Cancer. 2015 Oct;15(5):307-12. doi: 10.1016/j.clbc.2015.03.010. Epub 2015 Mar 25. Review.

PMID:
25922284
20.

Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.

Quagliata L, Klusmeier S, Cremers N, Pytowski B, Harvey A, Pettis RJ, Thiele W, Sleeman JP.

Clin Exp Metastasis. 2014 Mar;31(3):351-65. doi: 10.1007/s10585-013-9633-2. Epub 2013 Dec 31.

PMID:
24379135

Supplemental Content

Support Center